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We developed a unique protocol where transcranial direct current stimulation (tDCS) of
the motor cortex is performed during positron emission tomography (PET) scan using
a 1µ-opioid receptor (µOR) selective radiotracer, [ 1C]carfentanil. This is one of the most
important central neuromechanisms associated with pain perception and regulation. We
measured µOR non-displaceable binding potential (µOR BPND) in a trigeminal neuropathic
pain patient (TNP) without creating artifacts, or posing risks to the patient (e.g., monitoring
of resistance).The active session directly improved in 36.2% the threshold for experimental
cold pain in the trigeminal allodynic area, mandibular branch, but not theTNP patient’s clini-
cal pain. Interestingly, the single active tDCS application considerably decreasedµORBPND
levels in (sub)cortical pain-matrix structures compared to sham tDCS, especially in the pos-
terior thalamus. Suggesting that the µ-opioidergic effects of a single tDCS session are
subclinical at immediate level, and repetitive sessions are necessary to revert ingrained
neuroplastic changes related to the chronic pain. To our knowledge, we provide data for
the first time in vivo that there is possibly an instant increase of endogenous µ-opioid
release during acute motor cortex neuromodulation with tDCS.
Keywords: tDCS, PET, opioid receptors, neuroplasticity, trigeminal neuropathic pain, post-herpetic neuralgia
BACKGROUND
Pain is described as a complex experience affecting not only the
sensory, but also the affective and cognitive systems (Merskey and
Bogduk, 1994). Although the central mechanisms involved in pain
perception and modulation have not been completely elucidated,
recent years have seen significant advances in the understanding of
the anti-nociceptive mechanisms controlling the pain experience
in humans. One of the most important modulatory mechanisms
is the endogenous opioidergic system, which is involved in the
regulation of experimental and clinical pain, as well as in the
effects of analgesic opiate drugs. Studies with positron emission
tomography (PET) have shown decreased opioid receptor non-
displaceable binding potential (BPND) in patients with chronic
pain disorders, including rheumatoid arthritis (Jones et al., 1994),
neuropathic pain (Maarrawi et al., 2007a; DosSantos et al., 2012),
and fibromyalgia (Harris et al., 2007) when examined with both
selective for µ-opioid receptor (µOR; Harris et al., 2007; DosSan-
tos et al., 2012) and non-selective (Jones et al., 1994; Maarrawi
et al., 2007a) opioid receptor markers. The data available points to
either or both endogenous opioid release, and down-regulation of
opioid receptors. It has also been demonstrated that sustained
pain activates µOR mediated neurotransmission in a complex
network of brain areas related to pain, including the dorsolateral
prefrontal cortex, anterior cingulate, anterior and posterior insula,
thalamus, hypothalamus, amygdala, and periaqueductal gray mat-
ter. Furthermore, the magnitude of these regional activations was
related to the individual’s capacity to suppress sensory and affective
elements of the pain experience (Zubieta et al., 2001).
Therapies that directly modulate brain activity in spe-
cific neural networks might be particularly suited to relieve
chronic pain. Interestingly, a novel method of non-invasive
brain stimulation, namely transcranial direct current stimulation
(tDCS), has been reported to produce lasting therapeutic effects,
when applied to the motor cortex, in chronic pain disorders,
including fibromyalgia (Fregni et al., 2006; Riberto et al., 2011),
orofacial pain attributed to viral infection (Antal and Paulus,
2011), and chronic migraine (DaSilva et al., 2012). This technique
is based on the application of a weak direct current to the scalp that
flows between two electrodes (anode and cathode). Some studies
have shown that the efficacy of tDCS depends critically on para-
meters such as electrode position and current strength (Nitsche
et al., 2003). In fact, application of tDCS for 13 min to the motor
cortex can modulate cortical excitability for several hours (Nitsche
and Paulus, 2000, 2001). Two cortical areas have been explored in
pain studies using tDCS: primary motor cortex and dorsolateral
prefrontal cortex (Nitsche et al., 2008; DaSilva et al., 2011). In
the most common setup for pain research the anode is positioned
over the motor cortex (M1) and the cathode over the supra-orbital
area (DaSilva et al., 2011). It has been described that the cortical
excitability can be changed up to 40% with this method (DaSilva
et al., 2011). Regarding the specific area stimulated in M1, studies
with non-invasive brain stimulation have shown better results for
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facial pain with the stimulation of the hand cortical area (medially
located) and more significant improvement of hand pain when
the cortical area representing the face (more laterally located) is
stimulated. One possible explanation would be the direct effect of
tDCS/TMS on the thalamus, which could lead to stimulation of the
ventroposteromedial nucleus (VPM), responsible for the nocicep-
tive input from the face (Lefaucheur et al., 2004, 2006; Lefaucheur,
2006).
CASE PRESENTATION
SUBJECT
A 62-year-old woman was recruited by the Headache and Orofa-
cial Pain Effort (H.O.P.E.) laboratory at the University of Michigan
to participate in an ongoing study investigating the effects of the
tDCS in the µ-opioidergic system. She had a history of herpes
zoster in 2008, with severe pain, affecting the distribution of the
left ophthalmic (V1) and maxillary (V2) divisions of the trigem-
inal nerve. The pain persisted after the complete healing of the
initial lesions, leading to a diagnosis of post-herpetic neuralgia.
During the baseline evaluation, she described the pain as con-
stant, spontaneous, throbbing, aching, heavy, and hot-burning.
The average pain intensity was four out of ten and the average
of the unpleasantness associated with the spontaneous pain was
six out of ten. The pain was alleviated by sleep and massage and
aggravated by sleepiness, stress, and alcohol. The patient reported
eye dryness and nasal congestion related to her pain. The symp-
toms could not be triggered with heat, cold, touch, or chewing.
Her pain was not associated with nausea, vomiting, photopho-
bia, or headache. The patient rated the levels of social interaction
(0= isolation, 10= social gathering), attention (0= inattention,
10= high awareness), and anxiety (0= least, 10=most) at two,
three, and six out of ten, respectively, during the spontaneous pain.
She had been treated with amitriptyline 10 mg once a day and pre-
gabalin 50 mg twice a day, with only partial control of her pain.
The scores of the McGill Pain questionnaire (MPQ) descriptors
during the baseline evaluation were: 24 (sensory), 5 (affective), 2
(evaluative), and 7 (miscellaneous). The pain rating index (PRI)
was 38 and the present pain intensity (PPI) was three (distressing).
All procedures reported were carried out in accordance with the
bioethical rules for studies involving human beings of the WMA
(World Medical Association, 2012) – Declaration of Helsinki
(2008). The protocol of this study was previously approved by the
University of Michigan Investigational Review Board for Human
Subject Use and by the Radioactive Drug Research Committee of
the US Food and Drug Administration. The patient gave written
informed consent prior to the participation in the study.
NEUROIMAGING
We used a radiotracer with specific affinity for µORs, [11C]
carfentanil. The participant underwent one baseline and one
tDCS90-min PET scan using a Siemens (Knoxville, TN, USA)
HR+ scanner in 3D mode (reconstructed images have a full-width
at half maximum (FWHM) resolution of approximately 5.5 mm-
in-plane and 5.0 mm axially). Synthesis of high specific activity
[11C]carfentanil (>2000 Ci/mmol) was produced by the reac-
tion of [11C]methyliodide and a non-methyl precursor (Dannals
et al., 1985; Jewett, 2001). Each [11C]carfentanil dose (10–15 mCi,
≤0.03µg/kg) was administered at 50% as a bolus with the rem-
nants constantly injected across the session to reach normalized
tracer levels approximately 35 min after tracer administration.
Positron emission tomography images were reconstructed
using interactive algorithms into a 128× 128 pixel-matrix in a
28.8 cm diameter field of view (FOV). Twenty-eight image frames
were obtained and co-registered to one another. They were cor-
rected for motion and decay (Minoshima et al., 1993). Dynamic
image data for each scan were converted on a voxel-by-voxel basis
into two sets of parametric images: First, a tracer transport mea-
sure (K1 ratio) used for co-registration and normalization proce-
dures; and second,a receptor-related measure,distribution volume
ratio (DVR, equal to Bmax/K d+ 1 or binding potential at equilib-
rium (BPND)+ 1). These two measures were estimated using a
modified Logan graphical analysis using the occipital cortex as the
reference region (Logan et al., 1996).
A T1-weighted anatomical MRI scan was acquired on a 3 T
scanner (General Electric, Milwaukee, WI, USA). The MRI acqui-
sition utilized the following sequence parameters: axial spoiled-
gradient recalled (SPGR) 3D acquisition, 15.63 bandwidth, rep-
etition time [TR]= 9.2 ms, echo time [TE]= 1.9 ms, inversion
recovery preparation 500 ms, flip angle= 15˚, 25/26 FOV, num-
ber of excitations [NEX]= 1, 144 contiguous slices, 1.0 mm slice
thickness, 256× 256 matrix.
Images were anatomically standardized into template space
using Statistical Parametric Mapping (SPM8) software by (A) co-
registering the MR scan and K1 scans; (B) normalizing the MR scan
to the Montreal Neurologic Institute (MNI) template brain using
DARTEL; and (C) applying the resulting deformation matrix to
the PET images. Co-registration and normalization accuracy was
verified by comparing the transformed MR and PET images to the
MNI atlas template.
TRANSCRANIAL DIRECT CURRENT STIMULATION
Both placebo and active tDCS were applied during the second
PET scan. The placebo tDCS was applied during the early phase
of the exam (15–35 min), while the active tDCS during the late
phase (60–80 min). This sequence was adopted to avoid carry-over
effects from the placebo tDCS. In active stimulation 2 mA of tDCS
was applied for 20 min. The anode was placed over the area cor-
responding to the primary motor cortex (M1) while the cathode
was positioned over the supra-orbital region. For placebo tDCS,
the same method was used; however current was applied only for
30 s. This has been demonstrated to be a reliable method of sham
stimulation (Gandiga et al., 2006) as sensations arising from tDCS
treatment are observed usually at the beginning of application. The
impedance was controlled under 5 kΩ during the whole period
of active stimulation to avoid abnormal increase of the overall
resistance and consequently heat that could potentially burn the
patient. The tDCS protocol used in this study is fully explained in
a stepwise manner by our scientific team in DaSilva et al. (2011).
Due to the space restrictions, considering the stimulation inside
the PET scanner, a special system was developed to add more solu-
tion to the sponges when needed. This system consisted of two
syringes, each one connected to one sponge by two small tubes.
Each electrode was positioned inside a 35 cm2 sponge, that was
soaked with approximately 12 mL of saline solution (6 mL per
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side) before the PET and up to 12 mL during the procedure. We
used saline solutions with lower concentrations of NaCl (15 mM)
(DaSilva et al., 2011).
QUANTITATIVE SENSORY TESTING
In this study we controlled the effects of tDCS on the thermal per-
ception as assessed by the Quantitative Sensory Testing (QST)
in three moments during the second PET: before starting the
scan, in the period between sham and active tDCS (approximately
40–60 min) and after the scan. For this purpose, a QST protocol,
consisting of thermal pain thresholds for cold and hot stimuli,
was performed using a Thermal Sensory Analyzer TSA 2001-II
(Medoc, Israel) (Yarnitsky and Sprecher, 1994; Bachmann et al.,
2010). The thermal stimuli were applied upon V3, bilaterally, and
dorsal radial area of both hands. Each stimulus was applied for
three consecutive times and the average was calculated.
RESULTS
Levels of µOR BPND in our trigeminal neuropathic pain patient
(TNP) patient during a single tDCS application immediately
induced significant decrease inµOR binding in many (sub)cortical
pain-matrix structures, including nucleus accumbens (NAc), ante-
rior cingulate cortex (ACC), insula (Ins), and thalamus (Thal;
Figures 1 and 2). For instance, the M1-tDCS montage consider-
ably decreased µOR binding in the posterior thalamus (R: 21.5%;
L: 19.54%), compared to sham tDCS (R: 2.2%; L: 4.7%).
No significant changes were observed in the clinical pain levels
related to tDCS. The pain as assessed by the visual analog scale
(VAS) was four out of ten before the second PET, three after
placebo tDCS, and returned to four after the PET. Regarding the
QST, a significant increase in the temperature for heat threshold
was observed in the left V3 after sham tDCS and when compar-
ing baseline and active tDCS. On the hand, the temperature for
cold threshold showed a significant decrease in the left V3 after
active tDCS but not after placebo tDCS. When comparing the
cold threshold after active tDCS to the baseline threshold (before
starting the PET scan), there was a reduction of the temperature
at which cold pain was detected in the left V3 of approximately
36.2%. Significant changes in the heat and cold thresholds asso-
ciated with sham and active tDCS were also observed in other
regions, such as right V3, and right hand. The QST results are
presented in the Table 1.
DISCUSSION
To our knowledge, this is the first study showing an immediate
reduction in theµOR binding in response to an acute motor cortex
neuromodulation, suggesting that the analgesic effect of M1-tDCS
is possibly due to direct increase of endogenous opioid release.
Endogenous opioid systems have long been implicated in
regulating pain nociceptive signals, with µORs being the pri-
mary mediators of opiate analgesia, but also the rewarding and
tolerance-producing effects of opiates (Sora et al., 1997). Both ele-
ments, endogenous opioid release and µOR concentrations, are
therefore critical elements for the understanding of chronification
and alleviation of pain in TNP patients. The first direct evidence of
regional endogenous µ-opioid activation during sustained exper-
imental trigeminal pain in healthy humans was published by
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FIGURE 1 | Decrease in µ-opioid receptor binding associated with
transcranial direct current stimulation. Upper panel: µOR BPND during
the baseline PET. Lower panel: µOR BPND during active tDCS. ACC, anterior
cingulate cortex; NAc, nucleus accumbens; Ins, insula.
Zubieta et al. (2001) using PET, measured with external imaging
as reductions in the in vivo availability of µORs BPND quanti-
fied with [11C]carfentanil. Acute reductions in µOR BPND were
observed in the PAG, thalamus, hypothalamus, NAc, ventral pal-
lidum, amygdala, insula, and dorsal anterior cingulate (dACC),
correlating with suppression of sensory and affective qualities of
the pain challenge.
The investigation of the response of the endogenous opioid
system to TNP and its neuromodulation models is of impor-
tance to understand the mechanisms in place to regulate the
pain experience. This information is key to better predict the
varied responses of TNP patients to therapeutic interventions.
Jones et al. (1994, 1999) utilized [11C]diprenorphine, a non-
selective opioid radiotracer, to examine the in vivo availability
of opioid receptors in a small group of patients diagnosed with
rheumatoid arthritis and trigeminal neuralgia before and 3 weeks
to 3 months after treatment and pain relief. Substantial reduc-
tions in cortical and subcortical opioid receptor availability were
observed prior to treatment at resting state (baseline), which
were reversed after pain relief. Similar results were obtained with
[11C]diprenorphine in four central post stroke pain patients and
in a patient with a pontine infarction and pain (Willoch et al.,
1999, 2004), suggesting a dysregulation of central opioid mecha-
nisms at baseline in response to chronic pain, regardless of pain
etiology. Interestingly, in a study with eight refractory neuropathic
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FIGURE 2 | (A) Decreased thalamic µ-opioid receptor availability during active tDCS, represented in the coronal plane. (B) Bar chart illustrating the µ-opioid
receptor binding potential in the right and left thalamus during the late phase of the first and second PET scans.
Table 1 | Variations in the heat and cold thresholds related to placebo and active tDCS.
Region Heat/
cold
Before PET After
placebo
tDCS After active tDCS Significance level (p)
Mean SD Mean SD Mean SD Baseline ×
placebo
tDCS
Baseline ×
active
tDCS
Placebo ×
active
tDCS
Left V3 Heat 35.8 0.4 42.7 1.9 44.9 0.9 p<0.001 p<0.001 p>0.05
Right V3 Heat 42.2 0.8 43.6 1.1 44.1 1.1 NS NS NS
Left hand Heat 46.3 1.0 46.3 1.0 43.5 2.1 NS NS NS
Right hand Heat 44.2 1.0 40.0 1.1 44.2 1.9 p<0.05 p>0.05 p>0.05
Left V3 Cold 23.7 2.3 22.7 2.5 15.1 3.2 p>0.05 p<0.05 p<0.05
Right V3 Cold 20.1 3.8 20.2 3.8 9.5 5.9 p>0.05 p<0.05 p<0.05
Left hand Cold 15.1 6.8 18.3 6.8 12.9 4.3 NS NS NS
Right hand Cold 14.1 3.4 12.6 2.3 18.0 9.1 NS NS NS
Statistical significance (in bold) was defined at p<0.05 (one-way ANOVA followed by Tukey’s test).
pain patients, postoperative (invasive) motor cortex stimulation
induced decreases of [11C]diprenorphine binding in the anterior
mid-cingulate cortex (MCC) and PAG, which were significantly
correlated with pain relief (Maarrawi et al., 2007b). The authors
suggested that the decrease in binding of the exogenous ligand was
possibly due to receptor occupancy by enhanced release of endoge-
nous opioids. This analgesic mechanism is highly associated with
M1 cortex stimulation, at least with rTMS, since it is blocked with
naloxone injection (Taylor et al., 2012). tDCS over M1 induces
immediate changes in thermal sensory percepts in health subjects,
especially cold (Bachmann et al., 2010). In addition, it produces
long lasting pain relief in chronic pain patients, including TNP
(Lima and Fregni, 2008). Recently, it was reported that acute
tDCS modulates functional connectivity depending on its polarity
(Polania et al., 2011). Anodal stimulation over M1 with contralat-
eral frontocortical cathode placement (our protocol) immediately
increases functional coupling between ipsilateral M1 and thala-
mus. On the contrary, cathodal tDCS over M1 decreases functional
coupling between ipsilateral M1 and contralateral putamen.
The findings above hint why the anode M1/cathode
orbitofrontal electrode montage results in optimal modulation
of pain-matrix hyperactivity, specially the thalamus, which under-
lies chronic pain. Here, in our case report data with TNP, the
same active M1-tDCS montage considerably decreased µOR
binding in the posterior thalamus (Figure 2). Nonetheless, it
is possible that an additional opioid release might have been
prevented by a potential carry-over effect related to the sham
stimulation.
Remarkably, the single tDCS application immediately
improved 36.2% the threshold for experimental cold pain in
the allodynic V3 area (baseline: 23.7˚C± 2.3; placebo tDCS:
22.7˚C± 2.5; active tDCS 15.1˚C± 3.2), but not the TNP patient’s
clinical pain (baseline: 4, VAS 0-10); placebo tDCS: 3; active
tDCS: 4). Suggesting that the immediate opioidergic effects of
a single tDCS session are subclinical, and repetitive sessions are
necessary to revert ingrained neuroplastic changes related to the
chronic TNP suffering (see next paragraph). This is in agreement
with the results from multiple clinical tDCS studies, showing a
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direct relationship of patients’ clinical pain improvement with the
number of tDCS sessions (Lima and Fregni, 2008).
CONCLUDING REMARKS
This case report represents a change of paradigm, as we directly
modulated the same opioid mechanisms under study by applying
novel neuroimaging and neuromodulatory tools. Future studies
are necessary to confirm our results, and to investigate further the
effects of tDCS on the endogenous opioid system in a larger cohort
of patients.
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